Naia Pharmaceuticals

Welcome to Naia

 

We fund and develop companies that address regional and global unmet medical needs, utilizing our international base of operations to develop therapeutics better, faster, at lower cost and in proximity to target markets.

 

We look forward to working with you.

Our Values

Our Values

Nai`a is the Hawaiian name for spinner dolphins – renowned for their acrobatic behavior and symbolizing energy, creativity and positivity.  Their habitat is worldwide and they are known to be extremely social, forming collaborations amongst themselves and in Hawaii, even with local fishermen.

We chose the name Naia because we are building an international organization to bring creative solutions to worldwide health issues.  We rely on a growing network of collaborations, starting with our first investor, Pharco Pharmaceuticals of Alexandria, Egypt, and our renowned international Advisory Board.

We admire the spirit, energy and collaborative creativity of the Nai`a.  We are building our company around the same qualities.

Our Aims

Our Aim

Our aim is simple: To build globally focused biotechnology companies which, employing innovative business practices, deliver products to patients and physicians in the most efficient and cost-effective manner.

The vision, experience and dedication of our people is the foundation upon which we have built our organization and continues to drive our development. A powerful combination of cutting-edge clinical excellence and innovative business strategy is what allows us to continually meet and exceed expectations at every level.

Our focus is on addressing unmet medical needs. Our products are innovative and will, subject to successful development and approval, provide significant benefits to patients worldwide.

Our People

Our People

Naia’s management team and founders have extensive experience starting, building and managing companies globally, including the US, Europe, Middle East, Asia and South America.

Together, their backgrounds include academia, pharma, biotech, and diagnostics in a variety of leadership roles.

This experience, along with a shared vision for creating a nimble, flexible model for global drug development is an essential ingredient in Naia’s success.

Our Companies

Our Companies

We are building biotechnology companies that address unmet medical needs.

By creatively sourcing products for these companies and by financing and developing them globally, we aim to develop new products faster and more effectively than traditional biotech companies.

Naia’s first two companies are Naia Metabolic Inc and Naia Rare Diseases Inc and exemplify the types of company Naia is developing.

What are the experts saying?

What are the experts saying about Naia?

” … Knowing the individual backgrounds of the [Naia] management team, combined with the approach of the business model, it was immediately evident the right components where in place that could help Pharco to make a difference in emerging markets such as Egypt.”

Dr Sherine Helmy
CEO Pharco Pharmaceuticals

“Naia’s founding team has the deep worldwide relationships with academia and industry required to identify relevant innovative drug development opportunities, and to effectively bring these new medicines to their respective regions. Naia is building a diverse portfolio of late-stage preclinical and clinical assets that address critical regional and global unmet medical needs.”

Dr Omar Haffar
CEO EOS Biosciences

“Naia has … a unique model that allows financing and development flexibility, creating a robust portfolio of late-stage preclinical and clinical assets that will allow it to realize value quickly, inexpensively and at relatively low risk.”

Robert Williamson III
CEO PharmAkea

“Naia’s plan to use an efficient operating process, a global strategy to develop drugs incorporating early input from key stakeholders will lead to the development of cost-effective, innovative therapeutic solutions that can address the local and global healthcare needs.”

Dr Jorge Puente MD
Managing Partner at Pleasanton Pharma Ventures

“Naia’s management team has shown both passion and urgency to help the medical community advance and clinically evaluate a potentially life-changing new treatment for this incurable disease [Short Bowel Syndrome].”

Dr Mark Pimentel MD
Professor of Medicine and Director of the Gastrointestinal Motility Program
Cedars-Sinai Medical Center, Los Angeles

Latest Naia News

Latest Naia News

Naia Rare Diseases Announces Investigational New Drug Application Submission to Initiate Clinical Trials of NB 1001 for Short Bowel Syndrome

Naia Rare Diseases Announces Investigational New Drug Application Submission to Initiate Clinical Trials of NB 1001 for Short Bowel Syndrome   -- Mark Pimentel, MD, of Cedars-Sinai to be Principal Investigator--   RICHMOND, Calif, November 29, 2016 –Naia Rare...
Read More

Naia Rare Diseases to Present at 28th Annual ROTH Capital Conference

Naia Rare Diseases Inc to Present at 28th Annual ROTH Capital Conference on Tuesday, March 15, 2016 Richmond, CA--(Mar 11, 2016) – Naia Rare Diseases, Inc., a biotechnology company developing novel treatments for rare gastrointestinal diseases, today announced that it...
Read More

Naia Rare Diseases appoints Professor Palle Bekker Jeppesen to its Scientific Advisory Board

Naia Rare Diseases, Inc. appoints Professor Palle Bekker Jeppesen to its Scientific Advisory Board -- Appointment Completes Company’s Scientific Advisory Board -- RICHMOND, Calif., January 18, 2016 – Naia Limited, an international drug development company today...
Read More

Naia Rare Diseases Forms Scientific Advisory Board Comprised of Internationally Renowned Experts and Scientists

Naia Rare Diseases Inc, a subsidiary of Naia Limited, Forms Scientific Advisory Board Comprised of Internationally Renowned Experts and Scientists -- Company Appoints Advisor of Patient and Physician Relations -- RICHMOND, Calif., January 7, 2016 – Naia Limited, an...
Read More

Naia Rare Diseases granted orphan drug designation for NB1001

Naia Limited, an international drug development company today announced that its subsidiary, Naia Rare Diseases, has been granted by the U.S. Food and Drug Administration (FDA) orphan drug designation for NB1001, its long-acting GLP-1 receptor agonist, for the...
Read More

For more information, please contact us

here